Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (46)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2607-2616

  2. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

    Leukemia, Vol. 37, Núm. 2, pp. 388-395

  3. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories

    Frontiers in Oncology, Vol. 13

  4. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  5. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

  6. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

    Seminars in Hematology

  7. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

  8. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  9. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  10. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  11. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

  12. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

    HemaSphere

  13. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2022

  1. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

    Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1058-1069

  2. High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia

    Blood Advances

  3. IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385

  4. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62

  5. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Blood Advances

2021

  1. Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study

    Blood Advances, Vol. 5, Núm. 3, pp. 725-736